Pattern of disease expression in SLE patients with antiphospholipid antibodies : data from Indian Systemic Lupus Erythematosus Inception cohort (INSPIRE)
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Antiphospholipid antibodies (APLA) are present in one-third of systemic lupus erythematosus (SLE) patients, and they are associated with both criteria and non-criteria manifestations. We studied the prevalence, clinical associations, and impact on mortality of APLA in SLE patients from India. Among the Indian SLE inception cohort (INSPIRE), patients who had data on all five routinely performed APLAs [lupus anticoagulant (LA), IgG and IgM anticardiolipin antibody (aCL) and anti-β2-glycoprotein I(β2GPI)] at enrolment were selected. Patients were divided into four categories based on the presence/absence of APLA associated manifestations and presence/absence of the APLA viz SLE-APS, SLE-APLA, SLE: events but no APLA, and SLE: no events, no APLA (reference group). 1035 SLE patients at least 1 APLA antibody was detected in 372 (35.9%). LA was present in 206 (19.9%), aCL in 126 (12.2%) and β2-GPI in 178 (17.2%). There were 88 thrombotic events in 83 patients (8.0%); 73 (82.9%) being arterial; APLA positivity was present in 37 (44.6%) [AOR 1.70 (1.054, 2.76)]. SLE-APS patients were younger and had higher mortality [AOR 4.11 (1.51, 11.3)], neuropsychiatric and hematologic disease. SLE-APLA also had a higher mortality rate [AOR 2.94 (1.06, 8.22)] than the reference group. The mortality was highest in the subset of patients with thrombotic events in the presence of APLA [AOR 7.67 (1.25, 46.9)]. The mere presence of APLA also conferred higher mortality even in the absence of thrombotic events [AOR 3.51 (1.43, 8.63)]. Hematologic manifestations (36.1%) were the most common non-criteria-manifestation. One-third of SLE patients have APLA and its presence is associated with non-criteria hematologic manifestations, arterial thrombosis and higher mortality rate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Rheumatology international - 44(2024), 5 vom: 25. Apr., Seite 819-829 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shobha, Vineeta [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00296-023-05511-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365729272 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365729272 | ||
| 003 | DE-627 | ||
| 005 | 20240401232437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-023-05511-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM365729272 | ||
| 035 | |a (NLM)38082159 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shobha, Vineeta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pattern of disease expression in SLE patients with antiphospholipid antibodies |b data from Indian Systemic Lupus Erythematosus Inception cohort (INSPIRE) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a Antiphospholipid antibodies (APLA) are present in one-third of systemic lupus erythematosus (SLE) patients, and they are associated with both criteria and non-criteria manifestations. We studied the prevalence, clinical associations, and impact on mortality of APLA in SLE patients from India. Among the Indian SLE inception cohort (INSPIRE), patients who had data on all five routinely performed APLAs [lupus anticoagulant (LA), IgG and IgM anticardiolipin antibody (aCL) and anti-β2-glycoprotein I(β2GPI)] at enrolment were selected. Patients were divided into four categories based on the presence/absence of APLA associated manifestations and presence/absence of the APLA viz SLE-APS, SLE-APLA, SLE: events but no APLA, and SLE: no events, no APLA (reference group). 1035 SLE patients at least 1 APLA antibody was detected in 372 (35.9%). LA was present in 206 (19.9%), aCL in 126 (12.2%) and β2-GPI in 178 (17.2%). There were 88 thrombotic events in 83 patients (8.0%); 73 (82.9%) being arterial; APLA positivity was present in 37 (44.6%) [AOR 1.70 (1.054, 2.76)]. SLE-APS patients were younger and had higher mortality [AOR 4.11 (1.51, 11.3)], neuropsychiatric and hematologic disease. SLE-APLA also had a higher mortality rate [AOR 2.94 (1.06, 8.22)] than the reference group. The mortality was highest in the subset of patients with thrombotic events in the presence of APLA [AOR 7.67 (1.25, 46.9)]. The mere presence of APLA also conferred higher mortality even in the absence of thrombotic events [AOR 3.51 (1.43, 8.63)]. Hematologic manifestations (36.1%) were the most common non-criteria-manifestation. One-third of SLE patients have APLA and its presence is associated with non-criteria hematologic manifestations, arterial thrombosis and higher mortality rate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-β2-glycoprotein I | |
| 650 | 4 | |a Anticardiolipin antibody | |
| 650 | 4 | |a Antiphospholipid antibodies | |
| 650 | 4 | |a Antiphospholipid syndrome | |
| 650 | 4 | |a Lupus anticoagulant | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Non-criteria manifestations | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 650 | 4 | |a Thrombosis | |
| 650 | 7 | |a Antibodies, Antiphospholipid |2 NLM | |
| 650 | 7 | |a Antibodies, Anticardiolipin |2 NLM | |
| 650 | 7 | |a Lupus Coagulation Inhibitor |2 NLM | |
| 700 | 1 | |a Rajasekhar, Liza |e verfasserin |4 aut | |
| 700 | 1 | |a Manuel, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Nayana, V |e verfasserin |4 aut | |
| 700 | 1 | |a Kavadichanda, Chengappa |e verfasserin |4 aut | |
| 700 | 1 | |a Kounassegarane, Deepika |e verfasserin |4 aut | |
| 700 | 1 | |a Mathew, Ashish J |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Rathi, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Parasar |e verfasserin |4 aut | |
| 700 | 1 | |a Tripathy, Saumya Ranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Bidyut |e verfasserin |4 aut | |
| 700 | 1 | |a Selvam, Sumithra |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Abhishek Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Ankita |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Avinash |e verfasserin |4 aut | |
| 700 | 1 | |a Aggarwal, Amita |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d 1985 |g 44(2024), 5 vom: 25. Apr., Seite 819-829 |w (DE-627)NLM012644315 |x 1437-160X |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:5 |g day:25 |g month:04 |g pages:819-829 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00296-023-05511-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 5 |b 25 |c 04 |h 819-829 | ||